Payment overview · 2025
General Payments
$220.40
12 reported records · 9 companies
Healthcare provider profile · identity verified
Bryan A Hubl, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HEBRON, NE · NPI 1700867892
Verified facts
What the public records show
CMS Open Payments records show Bryan A Hubl, M.D. received $220.40 in general payments during 2025 across 12 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 37.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Relistor by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $81.49 | 37.0% | 4 | 2025 |
| SPR Therapeutics, Inc | Unresolved — no canonical attribution shown | $26.74 | 12.1% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $21.98 | 10.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.90 | 7.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.22 | 6.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.13 | 6.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.10 | 6.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.09 | 6.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.75 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $220.40 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $81.49 | 4 | 2025 |
Source payment records
|
|||||
| SPRINT PNS System Normalized: sprint pns system |
Device | SPR Therapeutics, Inc | $26.74 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.75 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 192 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
192 | 35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
192 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 519 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 497 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 491 | 88 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 442 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 409 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 403 | 87 |
| Lisinopril | Lisinopril | 382 | 86 |
| Furosemide | Furosemide | 371 | 73 |
| Losartan Potassium | Losartan Potassium | 358 | 77 |
| Omeprazole | Omeprazole | 345 | 84 |
| Meloxicam | Meloxicam | 318 | 55 |
| Gabapentin | Gabapentin | 302 | 54 |
| Metformin Hcl | Metformin Hcl | 297 | 60 |
| Potassium Chloride | Potassium Chloride | 287 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 254 | 52 |
| Simvastatin | Simvastatin | 206 | 44 |
| Jardiance | Empagliflozin | 192 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 186 | 45 |
| Montelukast Sodium | Montelukast Sodium | 162 | 25 |
| Allopurinol | Allopurinol | 160 | 35 |
| Tramadol Hcl | Tramadol Hcl | 157 | 31 |
| Carvedilol | Carvedilol | 151 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 151 | 28 |
| Eliquis | Apixaban | 138 | 27 |
| Spironolactone | Spironolactone | 131 | 31 |
| Prednisone | Prednisone | 128 | 84 |
| Warfarin Sodium | Warfarin Sodium | 122 | 16 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 120 | 77 |
| Escitalopram Oxalate | Escitalopram Oxalate | 117 | 24 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 116 | 115 |
| Famotidine | Famotidine | 116 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 22 |
| Alprazolam | Alprazolam | 113 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 109 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 96 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 16 |
| Glipizide | Glipizide | 92 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 92 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 22 |
| Atenolol | Atenolol | 84 | 20 |
| Sertraline Hcl | Sertraline Hcl | 83 | 18 |
| Trazodone Hcl | Trazodone Hcl | 83 | 18 |
| Xarelto | Rivaroxaban | 80 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 76 | 55 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 16 |
| Buspirone Hcl | Buspirone Hcl | 70 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 68 | 13 |
| Lorazepam | Lorazepam | 67 | 12 |
| Cefdinir | Cefdinir | 65 | 59 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | suppressed |
| Ezetimibe | Ezetimibe | 63 | 13 |
| Bupropion Xl | Bupropion Hcl | 62 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 62 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 62 | 13 |
| Azithromycin | Azithromycin | 56 | 46 |
| Fentanyl | Fentanyl | 55 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 18 |
| Methylprednisolone | Methylprednisolone | 49 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Estradiol | Estradiol | 43 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 11 |
| Entresto | Sacubitril/Valsartan | 41 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | suppressed |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 12 |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Glipizide Er | Glipizide | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Methotrexate | Methotrexate Sodium | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 31 |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | 11 |
| Amoxicillin | Amoxicillin | 34 | 26 |
| Synjardy | Empagliflozin/Metformin Hcl | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 22 |
| Finasteride | Finasteride | 28 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Nystatin | Nystatin | 27 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Levemir | Insulin Detemir | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Calcitriol | Calcitriol | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Misoprostol | Misoprostol | 24 | suppressed |
| Constulose | Lactulose | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Sulfasalazine | Sulfasalazine | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Austedo | Deutetrabenazine | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Ulticare | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Tenivac | Tetanus-Diphtheria Toxoids/Pf | 15 | 15 |
| Vilazodone Hcl | Vilazodone Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Droxidopa | Droxidopa | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 14 |
| Amitiza | Lubiprostone | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Relistor | Methylnaltrexone Bromide | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $220.40 · 12 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, Cologuard Collection Kit, EVENITY, Fluad, Flucelvax, JARDIANCE, MOUNJARO, SPRINT PNS System, XIFAXAN, YUPELRI, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error